Milestone Scientific Inc. (NYSE:MLSS - Get Free Report) Director Michael Mcgeehan sold 20,000 shares of the company's stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.78, for a total value of $15,600.00. Following the completion of the sale, the director now directly owns 575,273 shares in the company, valued at $448,712.94. This trade represents a 3.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Michael Mcgeehan also recently made the following trade(s):
- On Tuesday, September 24th, Michael Mcgeehan sold 209 shares of Milestone Scientific stock. The stock was sold at an average price of $1.00, for a total transaction of $209.00.
Milestone Scientific Stock Performance
MLSS stock traded up $0.13 during trading on Friday, hitting $0.93. The stock had a trading volume of 419,214 shares, compared to its average volume of 117,733. Milestone Scientific Inc. has a 1-year low of $0.52 and a 1-year high of $1.10. The stock has a market cap of $72.05 million, a price-to-earnings ratio of -13.21 and a beta of 1.10. The company's 50 day moving average price is $0.81 and its two-hundred day moving average price is $0.86.
Hedge Funds Weigh In On Milestone Scientific
A number of institutional investors have recently modified their holdings of the company. World Investment Advisors LLC acquired a new position in Milestone Scientific in the third quarter valued at $91,000. Geode Capital Management LLC boosted its position in shares of Milestone Scientific by 6.4% in the third quarter. Geode Capital Management LLC now owns 527,005 shares of the company's stock worth $480,000 after acquiring an additional 31,572 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Milestone Scientific in the third quarter valued at approximately $48,000. Institutional investors and hedge funds own 5.79% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. StockNews.com started coverage on shares of Milestone Scientific in a research report on Friday. They issued a "hold" rating on the stock. Benchmark reissued a "speculative buy" rating and set a $1.25 price target on shares of Milestone Scientific in a research report on Wednesday, November 20th.
Get Our Latest Stock Report on Milestone Scientific
About Milestone Scientific
(
Get Free Report)
Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.
See Also
Before you consider Milestone Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Scientific wasn't on the list.
While Milestone Scientific currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
